Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-analysis

Cancer Causes and Control

Volumn 26, Issue 4, 2015, Pages 589-600

  Huang, Xuan Zhang ^a   Gao, Peng ^a   Sun, Jing Xu ^a   Song, Yong Xi ^a   Tsai, Cheng Che ^a   Liu, Jing ^a   Chen, Xiao Wan ^a   Chen, Ping ^a   Xu, Hui Mian ^a   Wang, Zhen Ning ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Aspirin; Breast cancer; Cancer survival; Meta analysis; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; QUALITY CONTROL; BREAST NEOPLASMS; FEMALE; MORTALITY; TUMOR RECURRENCE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL;

EID: 84925465122     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0539-y     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
2. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100:44–52
3. Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ (2007) Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer 121:211–215
4. Kim HS, Moon HG, Han W et al (2012) COX2 overexpression is a prognostic marker for Stage III breast cancer. Breast Cancer Res Treat 132:51–59
5. Blair CK, Sweeney C, Anderson KE, Folsom AR (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101:191–197
6. Allott EH, Tse CK, Olshan AF, Carey LA, Moorman PG, Troester MA (2014) Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast Cancer Res Treat 147:415–421
7. Li Y, Brasky TM, Nie J et al (2012) Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev 21:239–242
8. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA (2011) Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf 20:131–137
9. Stang A (2010) Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605
10. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560
12. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
13. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101
14. Forget P, Bentin C, Machiels JP, Berliere M, Coulie PG, De Kock M (2014) Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth 113(Suppl 1):i82–i87
15. Forget P, Machiels JP, Coulie PG et al (2013) Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 20(Suppl 3):S650–S660
16. Holmes MD, Olsson H, Pawitan Y et al (2014) Aspirin intake and breast cancer survival—a nation-wide study using prospectively recorded data in Sweden. BMC Cancer 14:391
17. Murray LJ, Cooper JA, Hughes CM, Powe DG, Cardwell CR (2014) Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case–control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res 16:R34
18. Fraser DM, Sullivan FM, Thompson AM, McCowan C (2014) Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer 111:623–627
19. Bowers LW, Maximo IX, Brenner AJ et al (2014) NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin–aromatase interactions. Cancer Res 74:4446–4457
20. Barron TI, Flahavan EM, Sharp L, Bennett K, Visvanathan K (2014) Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I–III breast cancer: a nationwide population-based cohort study. Cancer Res 74:4065–4077
21. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28:1467–1472
22. Valsecchi ME, Pomerantz SC, Jaslow R, Tester W (2009) Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors. Clin Breast Cancer 9:225–230
23. Kwan ML, Habel LA, Slattery ML, Caan B (2007) NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18:613–620
24. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA (2000) Nested case–control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 83:112–120
25. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z (2012) Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379:1591–1601
26. Rozic JG, Chakraborty C, Lala PK (2001) Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93:497–506
27. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362–366
28. Lala PK, Al-Mutter N, Orucevic A (1997) Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 73:371–380
29. Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123–134
30. Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial–mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590
31. Hudson AG, Gierach GL, Modugno F et al (2008) Nonsteroidal anti-inflammatory drug use and serum total estradiol in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17:680–687
32. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B (2007) Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 166:709–716
33. Marshall SF, Bernstein L, Anton-Culver H et al (2005) Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 97:805–812
34. Terry MB, Gammon MD, Zhang FF et al (2004) Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 291:2433–2440
35. Robertson FM, Parrett ML, Joarder FS et al (1998) Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 122:165–175
36. Alshafie GA, Harris RE, Robertson FM, Parrett ML, Ross M, Abou-Issa H (1999) Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas. Anticancer Res 19:3031–3036
37. Hwang D, Scollard D, Byrne J, Levine E (1998) Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90:455–460
38. Jeong HS, Kim JH, Choi HY, Lee ER, Cho SG (2010) Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047. Oncol Rep 24:351–356
39. McFadden DW, Riggs DR, Jackson BJ, Cunningham C (2006) Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro. Int J Oncol 29:1019–1023
40. Chow LW, Yip AY, Chu WP, Loo WT, Toi M (2011) Bone metabolism and quality-of-life of postmenopausal women with invasive breast cancer receiving neoadjuvant hormonal therapy: sub-analyses from celecoxib anti-aromatase neoadjuvant (CAAN) trial. J Steroid Biochem Mol Biol 125:112–119
41. Chow LW, Cheng CW, Wong JL, Toi M (2005) Serum lipid profiles in patients receiving endocrine treatment for breast cancer—the results from the celecoxib anti-aromatase neoadjuvant (CAAN) trial. Biomed Pharmacother 59(Suppl 2):S302–S305
42. Brandao RD, Veeck J, Van de Vijver KK et al (2013) A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 15:R29
43. Goss PE, Ingle JN, Pritchard KI et al (2013) Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27—a randomized controlled phase III trial. J Clin Oncol 31:1398–1404
44. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071–1080